display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced OC (mOC) - 1st line (L1)
mOC - L1 - all population
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC IMagyn-050 ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons